Tao Yan1, Poornima Venkat1, Michael Chopp1, Alex Zacharek1, Ruizhuo Ning1, Cynthia Roberts1, Yi Zhang1, Mei Lu1, Jieli Chen2. 1. From the Tianjin Neurological and Gerontology Institute, Department of Neurology of Tianjin Medical University General Hospital, China (T.Y., J.C.); Department of Neurology (T.Y., P.V., M.C., A.Z., R.N., C.R., Y.Z., J.C.) and Department of Biostatistics and Research Epidemiology (M.L.), Henry Ford Hospital, Detroit, MI; and Department of Physics, Oakland University, Rochester, MI (M.C.). 2. From the Tianjin Neurological and Gerontology Institute, Department of Neurology of Tianjin Medical University General Hospital, China (T.Y., J.C.); Department of Neurology (T.Y., P.V., M.C., A.Z., R.N., C.R., Y.Z., J.C.) and Department of Biostatistics and Research Epidemiology (M.L.), Henry Ford Hospital, Detroit, MI; and Department of Physics, Oakland University, Rochester, MI (M.C.). jieli@neuro.hfh.edu.
Abstract
BACKGROUND AND PURPOSE: Comorbidity of diabetes mellitus and stroke results in worse functional outcome, poor long-term recovery, and extensive vascular damage. We investigated the neurorestorative effects and mechanisms of stroke treatment with human bone marrow-derived mesenchymal stromal cells (hMSCs) in type 2 diabetes mellitus (T2DM) rats. METHODS: Adult male Wistar rats were induced with T2DM, subjected to 2 hours of middle cerebral artery occlusion (MCAo) and treated via tail-vein injection with (1) PBS (n=8) and (2) hMSCs (n=10; 5×106) at 3 days after MCAo. RESULTS: In T2DM rats, hMSCs administered at 3 days after MCAo significantly improves neurological function without affecting blood glucose, infarct volume, and incidence of brain hemorrhage in comparison to T2DM-MCAo PBS-treated rats. Delayed hMSC treatment of T2DM stroke significantly improves blood-brain barrier integrity, increases vascular and arterial density and cerebral vascular perfusion, and promotes neuroblast cell migration and white matter remodeling as indicated by increased doublecortin, axon, myelin, and neurofilament density, respectively. Delayed hMSC treatment significantly increases platelet-derived growth factor expression in the ischemic brain, decreases proinflammatory M1 macrophage and increases anti-inflammatory M2 macrophage compared to PBS-treated T2DM-MCAo rats. In vitro data show that hMSCs increase subventricular zone explant cell migration and primary cortical neuron neurite outgrowth, whereas inhibition of platelet-derived growth factor decreases hMSC-induced subventricular zone cell migration and axonal outgrowth. CONCLUSIONS: In T2DM stroke rats, delayed hMSC treatment significantly improves neurological functional outcome and increases neurorestorative effects and M2 macrophage polarization. Increasing brain platelet-derived growth factor expression may contribute to hMSC-induced neurorestoration.
BACKGROUND AND PURPOSE: Comorbidity of diabetes mellitus and stroke results in worse functional outcome, poor long-term recovery, and extensive vascular damage. We investigated the neurorestorative effects and mechanisms of stroke treatment with human bone marrow-derived mesenchymal stromal cells (hMSCs) in type 2 diabetes mellitus (T2DM) rats. METHODS: Adult male Wistar rats were induced with T2DM, subjected to 2 hours of middle cerebral artery occlusion (MCAo) and treated via tail-vein injection with (1) PBS (n=8) and (2) hMSCs (n=10; 5×106) at 3 days after MCAo. RESULTS: In T2DM rats, hMSCs administered at 3 days after MCAo significantly improves neurological function without affecting blood glucose, infarct volume, and incidence of brain hemorrhage in comparison to T2DM-MCAo PBS-treated rats. Delayed hMSC treatment of T2DM stroke significantly improves blood-brain barrier integrity, increases vascular and arterial density and cerebral vascular perfusion, and promotes neuroblast cell migration and white matter remodeling as indicated by increased doublecortin, axon, myelin, and neurofilament density, respectively. Delayed hMSC treatment significantly increases platelet-derived growth factor expression in the ischemic brain, decreases proinflammatory M1 macrophage and increases anti-inflammatory M2 macrophage compared to PBS-treated T2DM-MCAo rats. In vitro data show that hMSCs increase subventricular zone explant cell migration and primary cortical neuron neurite outgrowth, whereas inhibition of platelet-derived growth factor decreases hMSC-induced subventricular zone cell migration and axonal outgrowth. CONCLUSIONS: In T2DM stroke rats, delayed hMSC treatment significantly improves neurological functional outcome and increases neurorestorative effects and M2 macrophage polarization. Increasing brain platelet-derived growth factor expression may contribute to hMSC-induced neurorestoration.
Authors: Anne M Taylor; Mathew Blurton-Jones; Seog Woo Rhee; David H Cribbs; Carl W Cotman; Noo Li Jeon Journal: Nat Methods Date: 2005-08 Impact factor: 28.547
Authors: Hua Teng; Zheng Gang Zhang; Lei Wang; Rui Lan Zhang; Li Zhang; Dan Morris; Sara R Gregg; Zhenhua Wu; Angela Jiang; Mei Lu; Berislav V Zlokovic; Michael Chopp Journal: J Cereb Blood Flow Metab Date: 2007-10-31 Impact factor: 6.200
Authors: Maurizio Paciaroni; Giancarlo Agnelli; Valeria Caso; Francesco Corea; Walter Ageno; Andrea Alberti; Alessia Lanari; Sara Micheli; Luca Bertolani; Michele Venti; Francesco Palmerini; Antonia M R Billeci; Giancarlo Comi; Paolo Previdi; Giorgio Silvestrelli Journal: Cerebrovasc Dis Date: 2009-06-05 Impact factor: 2.762
Authors: Kar Wey Yong; Jane Ru Choi; Mehdi Mohammadi; Alim P Mitha; Amir Sanati-Nezhad; Arindom Sen Journal: Stem Cells Int Date: 2018-10-08 Impact factor: 5.443